Showing results (1-10 of 400) with videos related to
Sort By:
Pageof 40
Clinical Pharmacology and Therapeutics|June 8, 2018
Opioids: The Painful Public Health RealityRachel F Tyndale, Edward M SellersTherapeutic Drug Monitoring|January 24, 2002
Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behaviorRachel F Tyndale, Edward M SellersClinical Pharmacology and Therapeutics|March 1, 2005
Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependenceViba Malaiyandi, Edward M Sellers, Rachel F TyndaleNicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco|August 8, 2008
Socioeconomic and drug use determinants of smoking status in an urban adult population of Black African descentJill C Mwenifumbo, Edward M Sellers, Rachel F TyndalePharmacogenomics|April 26, 2002
The role of pharmacogenetically-variable cytochrome P450 enzymes in drug abuse and dependenceLisa A Howard, Edward M Sellers, Rachel F TyndaleDrug and Alcohol Dependence|December 13, 2006
Nicotine metabolism and CYP2A6 activity in a population of black African descent: impact of gender and light smokingJill C Mwenifumbo, Edward M Sellers, Rachel F TyndaleDrug Discovery Today|June 24, 2003
Decreasing smoking behaviour and risk through CYP2A6 inhibitionEdward M Sellers, Rachel F Tyndale, Leona C FernandesAdvanced Drug Delivery Reviews|October 31, 2002
CYP2A6 genetic variation and potential consequencesChun Xu, Shari Goodz, Edward M Sellers, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 21, 2003
Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitroWenjiang Zhang, Yamini Ramamoorthy, Rachel F Tyndale, et al.Molecular Pharmacology|December 19, 2002
Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administrationKerri A Schoedel, Edward M Sellers, Roberta Palmour, et al.Pageof 40